CANbridge Pharma expands rare disease program
Chinese drug maker CANbridge Pharmaceuticals has announced a new partnership with the UMass Medical School to research and develop gene therapies for rare genetic conditions.
“CANbridge has a strong interest in deepening our rare disease pipeline and gene therapy is considered … the next generation pipeline for rare disease treatment after enzyme replacement, after antibodies, so naturally we need to really plan forward,” James Xue, founder, chairman and CEO of CANbridge, told STAT.
The Beijing-based rare disease specialist is one of a handful of companies focusing on conditions with hardly any treatment options in China. In 2018, the company signed a strategic partnership with Wuxi Biologics to discover and develop a portfolio of rare disease therapies, which now make up half of its pipeline.
Last year, CANBridge in-licensed Hunterase, an enzyme replacement therapy for genetic disorder Hunter syndrome, from South Korea’s GC Pharma. The drug is currently under priority review by China’s National Medical Products Administration, or NMPA, and is expected to be approved this year.
CANbridge has also commercialized two in-licensed cancer products in China – Caphosol from Jazz Pharmaceuticals’s subsidiary EUSA Pharma and Nerlynx from Puma Biotechnology – to support the development costs for its ongoing clinical programs.
“CANbridge has a strong interest in deepening our rare disease pipeline and gene therapy is considered … the next generation pipeline for rare disease treatment after enzyme replacement, after antibodies, so naturally we need to really plan forward,” James Xue, founder, chairman and CEO of CANbridge, told STAT.
The Beijing-based rare disease specialist is one of a handful of companies focusing on conditions with hardly any treatment options in China. In 2018, the company signed a strategic partnership with Wuxi Biologics to discover and develop a portfolio of rare disease therapies, which now make up half of its pipeline.
Last year, CANBridge in-licensed Hunterase, an enzyme replacement therapy for genetic disorder Hunter syndrome, from South Korea’s GC Pharma. The drug is currently under priority review by China’s National Medical Products Administration, or NMPA, and is expected to be approved this year.
CANbridge has also commercialized two in-licensed cancer products in China – Caphosol from Jazz Pharmaceuticals’s subsidiary EUSA Pharma and Nerlynx from Puma Biotechnology – to support the development costs for its ongoing clinical programs.
.png)
No hay comentarios:
Publicar un comentario